p38 MAP Kinase Inhibitor XX, FGA-19

P38 MAP Kinase Inhibitor XX, FGA-19

A p38 MAP kinase inhibitor

Cat. No.: AUR10722

CAS Number: N/A

Documents:

SizePrice

10 mg

$ 145

Tags FGA-19 FGA19 p38 MAP kinase inhibitor Auroramedbiochem

Alternate Names

N-(5-chloro-2-methylphenyl)-4-nitro-2,1,3-benzoxadiazol-7-amine

Appearance

Orange red solid

Formulation

N/A

CAS Number

N/A

Molecular Formula

C13H9ClN4O3

Molecular Weight

304.69

Purity

≥96% by HPLC

Solubility

DMSO (100 mg/ml)

Handling

Protect from air and light

Country of origin

USA

Storage temperature

+2 to +8 ◦C

Shipping Condition

Shelf life

24 months

MDL number

N/A

PubChem CID

71523686

SMILES

CC1=C(C=C(C=C1)Cl)NC2=CC=C(C3=NON=C23)[N+](=O)[O-]

InChI

InChI=1S/C13H9ClN4O3/c1-7-2-3-8(14)6-10(7)15-9-4-5-11(18(19)20)13-12(9)16-21-17-13/h2-6,15H,1H3

InChI key

IHECKWLNDYRDCT-UHFFFAOYSA-N

FGA-19 is a cell-permeable, benzoxadiazole compound designed to target p38 c-terminal "docking domain" that mediates interactions with upstream regulators and downstream substrates outside p38 active center. Selectively inhibits MEF-2A phosphorylation by activated p38α (IC50 = 6.31 µM; [p38] = 1 nM, [MEF-2a] = 10 nM, [ATP] = 25 µM) with little or no potency against a panel of other kinases or the docking site interaction-independent MBP phosphorylation by p38.